The Trump administration has decided to let a Medicare cushion expire, and the timing lands squarely on drug-plan shoppers. On July 28, 2026, the Centers for Medicare and Medicaid Services said it will end the Part D Premium Stabilization Demonstration at the close of this year, removing a subsidy that has quietly held down premiums on standalone prescription drug plans since 2025. Roughly 25 million people carry those plans. Whether an individual pays more in 2027 depends on the plan and the region, but the guardrail that kept increases small is being pulled just as insurers set next year’s prices.
The subsidy that quietly capped standalone drug premiums
The demonstration was never a household name, which is part of why its end has drawn little attention outside the industry. It launched in contract year 2025 as a voluntary program for standalone prescription drug plans, created to smooth out the premium swings that followed the benefit redesign in the Inflation Reduction Act. That redesign capped out-of-pocket drug spending but shifted more cost onto plans, and insurers responded by raising premiums. The subsidy was built to blunt that reaction.
Its mechanics were straightforward. Standalone plans received a flat direct payment of about $15 per member each month applied against the base premium, and any year-over-year premium increase was held to no more than $35. Together those two levers kept sticker prices from spiking and gave the market time to adjust. CMS now says plan sponsors have enough experience under the redesigned benefit to price accurately without the crutch, and it is discontinuing the demonstration at the end of CY 2026 to return the program to what it calls traditional market conditions.
Free retirement updates: Enrollment and claim windows come and go, and missing one can cost real money. The free Retirement Shield newsletter keeps readers ahead of the deadlines that matter. Sign up free.
Why about 25 million enrollees are exposed
The exposure is concentrated in one corner of Medicare. Standalone Part D plans are the drug-only policies that pair with Original Medicare, distinct from the drug coverage bundled inside Medicare Advantage. About 25 million beneficiaries hold these standalone plans, and they are the ones who felt the subsidy and will feel its absence. When the payment and the $35 cap disappear, insurers regain full latitude to price 2027 coverage on their own reading of costs.
That does not guarantee a jump for everyone. According to NPR’s reporting on the decision, some enrollees could see higher premiums, some little change, and some even a modest decrease, depending on how their specific plan and market react. The administration has argued the disruption will be contained. CMS Administrator Mehmet Oz said in late July that premiums for most beneficiaries would rise by less than $10 a month, framing the move as a return to normal competition rather than a cost shock.
Critics see the arithmetic differently. Removing a flat subsidy and a hard cap in the same year gives insurers room to recover costs they had been absorbing, and the enrollees with the least room in their budgets are often those on fixed Social Security income. For a household already tracking every recurring charge, even a single-digit monthly increase compounds across a year and stacks on top of other 2027 Medicare changes.
The benefit itself is not shrinking, which is the nuance that gets lost in the alarm. The Inflation Reduction Act redesign that prompted the subsidy also capped what any Part D enrollee pays out of pocket for covered drugs at $2,000 a year, and that ceiling stays in place for 2027. What the demonstration’s end changes is the monthly premium to buy into that richer coverage, not the $2,000 limit behind it, so a household could face a higher premium and still spend far less at the pharmacy counter than it would have in the years before the cap existed. The pressure lands on the entry price, not the protection.
What to watch before the 2027 prices post
The critical detail is that no one yet knows their exact 2027 number. CMS said it will release the final Medicare Advantage and Part D landscape, including average premiums and individual plan details, in September, once all offerings are finalized. Until then, the end of the subsidy is confirmed but the dollar effect on any given plan is not. That gap is the reason to pay attention rather than assume the worst or shrug it off.
The practical consequence for standalone-plan holders is that comparison shopping matters more this fall than in the recent past. When the subsidy flattened premiums, plans looked more alike on price, and staying put carried little penalty. Without it, the spread between plans can widen, and the plan that was cheapest in 2026 may not be cheapest in 2027. The Medicare Open Enrollment period, which runs each fall through December 7, is the window to switch drug plans without penalty.
The larger picture is that the end of the demonstration arrives alongside a redesigned benefit that already changed how much enrollees pay at the pharmacy counter. A retiree who reviews only the premium and ignores the formulary, the deductible, and the pharmacy network can end up paying more overall even if the headline premium looks flat. The subsidy’s expiration does not force anyone into a worse plan, but it removes the automatic protection that made inattention cheap, and it puts the burden of finding the best 2027 price back on the person holding the card.
This article was produced with AI assistance and reviewed against primary sources by The Money Overview editorial team.
More Financial Reading
